Prime Medicine, Inc. ( PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease November 12, 2025 8:00 AM EST ...

Prime Medicine announces positive Phase 1/2 data for PM359, leadership changes, and strategic pipeline prioritization, focusing on liver diseases. Prime Medicine, Inc. announced initial positive data ...

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.44 per share a year ago. These ...

A live audio webcast of the fireside chat will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other gene ...

We recently compiled a list of the 10 Most Shorted Stocks That Are Loved by Analysts. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other ...

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.44 per share a year ago. These figures ...